Previous 10 | Next 10 |
2023-05-03 07:05:40 ET Ionis Pharmaceuticals press release ( NASDAQ: IONS ): Q1 GAAP EPS of -$0.87 beats by $0.04 . Revenue of $131M (-7.7% Y/Y) beats by $4.12M . "Our first quarter results were in line with our expectations. We generated meaningful revenue whi...
Ionis reports first quarter 2023 financial results PR Newswire QALSODY approved for SOD1-ALS; MAA under review in EU Reported positive Phase 3 eplontersen ATTRv-PN data; December 22, 2023 PDUFA date On track to achieve 2023 financial guidance ...
FDA approves QALSODY™ (tofersen) as the first treatment targeting a genetic cause of ALS PR Newswire Accelerated approval marks a scientific advancement in treatment of superoxide dismutase 1 (SOD1)-amyotrophic lateral sclerosis (ALS) Approval based on reducti...
2023-04-25 13:46:35 ET The FDA announced Tuesday the approval of Qalsody (tofersen) developed by Biogen ( NASDAQ: BIIB ) and Ionis Pharmaceuticals ( IONS ) for certain patients with neurodegenerative disease amyotrophic lateral sclerosis (ALS). Specifically, the FDA has clea...
2023-04-24 08:12:36 ET Eplontersen, a late-stage candidate from Ionis Pharmaceuticals ( NASDAQ: IONS ) and AstraZeneca ( NASDAQ: AZN ) for hereditary transthyretin-mediated amyloid polyneuropathy (ATTRv-PN), met all primary and secondary endpoints in a phase 3 trial at 6...
Eplontersen halted ATTRv-PN disease progression and improved neuropathy impairment and quality of life in Phase 3 study through 66 weeks PR Newswire NEURO-TTRansform study met all co-primary and secondary endpoints Positive results to be presented today at AAN 2023...
2023-04-22 10:00:52 ET Get ahead of the market by subscribing to Seeking Alpha's Stocks to Watch, a preview of key events scheduled for the coming week. The newsletter keeps you informed of the biggest stories set to make headlines, including upcoming IPOs, investor days, earnings reports a...
2023-04-21 15:00:36 ET Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Check out Saturday morning's regular Stocks to Watch article for a full list of events planned for the week or the Seeking Alpha earnings calendar ...
Ionis to hold first quarter 2023 financial results webcast PR Newswire Webcast scheduled for Wednesday, May 3 at 11:30 a.m. Eastern Time CARLSBAD, Calif. , April 20, 2023 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) announced today t...
2023-04-19 09:15:00 ET British drugmaker AstraZeneca (NASDAQ: AZN) and U.S.-based Ionis Pharmaceuticals (NASDAQ: IONS) have been working jointly on a drug candidate for treating a rare disease known as transthyretin (ATTR) amyloidosis polyneuropathy. The potential medication...
News, Short Squeeze, Breakout and More Instantly...
Ionis Pharmaceuticals Inc. Company Name:
IONS Stock Symbol:
NASDAQ Market:
Ionis Pharmaceuticals Inc. Website:
Ionis announces positive detailed results from the HALOS Study of ION582 in people with Angelman syndrome PR Newswire ION582 showed robust and consistent benefit in communication, cognition and motor function in a broad patient population evaluated with a comprehensive set o...
Ionis to hold second quarter 2024 financial results webcast PR Newswire Webcast scheduled for Thursday, August 1 at 11:30 a.m. Eastern Time CARLSBAD, Calif. , July 19, 2024 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) announced ...
Ionis completes enrollment in pivotal trial evaluating zilganersen in people living with Alexander disease PR Newswire Zilganersen is the first investigational medicine in clinical development for people with Alexander disease, a rare, life-threatening neurological condition...